Lombard Medical Technologies Plc, a medical device company which is delisting its shares in London and offering them in the United States via a Cayman Islands holding company, reported a 13% increase in 2013 revenues to $7 million and a 52.7% increase in its operating loss to $20 million.
Life Science Partners (LSP) of Amsterdam, the Netherlands has announced the closing of a new fund that will invest in companies with marketable products in the areas of medical technology, diagnostics and e-health. The fund has raised €112 million from private investors.
Verona Pharma Plc, which develops medicines for respiratory diseases, has announced a share placement, subscription, and open offer with the intention of raising up to £14 million before expenses. The funds will be used to develop a compound for COPD.
Oxford Gene Technology Ltd, which provides equipment for genetics research, has acquired Cytocell Ltd, a Cambridge, UK-based supplier of probes for detecting DNA sequences called fluorescence in situ hybridisation or FISH. Financial terms were not disclosed.
Advanced Accelerator Applications SA, a French manufacturer of nuclear medicine products, is set to acquire Imaging Equipment Ltd, a privately-held UK distributor of nuclear medicine supplies, including products made by AAA.
Transgene SA, a French company specialising in oncolytic virus therapies, plans to raise €45.5 million with a partially underwritten equity offering on the Euronext Paris stock exchange. The company is offering 4,553,551 new ordinary shares at €10 per share.
Bavarian Nordic A/S has secured a new contract with an agency of the US government for its vaccine technology, this time with the Defense Threat Reduction Agency (DTRA), part of the Department of Defense.
Roche has entered into a collaboration with a two-year old UK company, Discuva Ltd, to discover and develop new antibiotics to treat infections caused by multi-drug resistant Gram-negative bacteria – the most difficult-to-treat bacteria.
Abingworth LLP has raised £225 million from investors for its tenth life sciences fund that will provide venture capital to companies in Europe and the US. The proceeds exceeded the investment group’s target of £200 million.
InDex Pharmaceuticals AB of Sweden has raised $20 million (€15 million) in a share placement with institutional investors ahead of the release of data from a late-stage trial of its lead product Kappaproct for severe ulcerative colitis.